The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1686
Addendum: Over-the-Counter Narcan Nasal Spray
Download PDF:   US English
Med Lett Drugs Ther. 2023 Oct 2;65(1686):160   doi:10.58347/tml.2023.1686f
Disclosures
Objective(s)
 Select a term to see related articles  naloxone   Narcan   opioid use disorder   RiVive 

Since the publication of our articles entitled Drugs for Opioid Use Disorder and In Brief: Over-the-Counter Narcan Nasal Spray earlier this year, Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone, has become available for sale over the counter (OTC). According to the manufacturer, the retail price for a box containing 2 doses is $44.99. Some insurance companies have announced plans to cover OTC purchase of the drug for their members.

RiVive (Harm Reduction Therapeutics), a 3-mg naloxone nasal spray recently FDA-approved for OTC sale, is expected to be marketed early next year.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article